GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (NAS:ONCY) » Definitions » Shiller PE Ratio

Oncolytics Biotech (Oncolytics Biotech) Shiller PE Ratio : (As of Apr. 28, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Oncolytics Biotech Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Oncolytics Biotech Shiller PE Ratio Historical Data

The historical data trend for Oncolytics Biotech's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolytics Biotech Shiller PE Ratio Chart

Oncolytics Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Oncolytics Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Oncolytics Biotech's Shiller PE Ratio

For the Biotechnology subindustry, Oncolytics Biotech's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncolytics Biotech's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncolytics Biotech's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Oncolytics Biotech's Shiller PE Ratio falls into.



Oncolytics Biotech Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Oncolytics Biotech's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Oncolytics Biotech's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.037/125.4675*125.4675
=-0.037

Current CPI (Dec. 2023) = 125.4675.

Oncolytics Biotech Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.513 98.604 -0.653
201406 -0.439 99.473 -0.554
201409 -0.431 99.394 -0.544
201412 -0.330 98.367 -0.421
201503 -0.301 99.789 -0.378
201506 -0.230 100.500 -0.287
201509 -0.143 100.421 -0.179
201512 -0.208 99.947 -0.261
201603 -0.215 101.054 -0.267
201606 -0.147 102.002 -0.181
201609 -0.217 101.765 -0.268
201612 -0.330 101.449 -0.408
201703 -0.213 102.634 -0.260
201706 -0.241 103.029 -0.293
201709 -0.163 103.345 -0.198
201712 -0.251 103.345 -0.305
201803 -0.240 105.004 -0.287
201806 -0.206 105.557 -0.245
201809 -0.153 105.636 -0.182
201812 -0.208 105.399 -0.248
201903 -0.202 106.979 -0.237
201906 -0.196 107.690 -0.228
201909 -0.121 107.611 -0.141
201912 -0.630 107.769 -0.733
202003 -0.029 107.927 -0.034
202006 -0.125 108.401 -0.145
202009 -0.121 108.164 -0.140
202012 -0.172 108.559 -0.199
202103 -0.103 110.298 -0.117
202106 -0.106 111.720 -0.119
202109 -0.071 112.905 -0.079
202112 -0.109 113.774 -0.120
202203 -0.095 117.646 -0.101
202206 -0.070 120.806 -0.073
202209 -0.060 120.648 -0.062
202212 -0.110 120.964 -0.114
202303 -0.074 122.702 -0.076
202306 -0.090 124.203 -0.091
202309 -0.103 125.230 -0.103
202312 -0.037 125.468 -0.037

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Oncolytics Biotech  (NAS:ONCY) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Oncolytics Biotech Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncolytics Biotech (Oncolytics Biotech) Business Description

Traded in Other Exchanges
Address
322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5
Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives. The primary focus is to advance programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies.

Oncolytics Biotech (Oncolytics Biotech) Headlines

From GuruFocus